HBV genotype B is associated with better response to interferon therapy in HBeAg( + ) chronic hepatitis than genotype C
dc.contributor.author | Wai, Chun-Tao | en_US |
dc.contributor.author | Chu, Chi-Jen | en_US |
dc.contributor.author | Hussain, Munira T. | en_US |
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.date.accessioned | 2006-04-28T16:57:05Z | |
dc.date.available | 2006-04-28T16:57:05Z | |
dc.date.issued | 2002-12 | en_US |
dc.identifier.citation | Wai, Chun Tao; Chu, Chi-Jen; Hussain, Munira; Lok, Anna S. F. (2002)."HBV genotype B is associated with better response to interferon therapy in HBeAg( + ) chronic hepatitis than genotype C." Hepatology 36(6): 1425-1430. <http://hdl.handle.net/2027.42/38415> | en_US |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.issn | 1527-3350 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/38415 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12447868&dopt=citation | en_US |
dc.description.abstract | Hepatitis B virus (HBV) genotype and precore/core promoter mutations have been implicated in spontaneous and interferon alfa (IFN-Α)—related hepatitis B e antigen (HBeAg) seroconversion. We performed a retrospective analysis of a previously reported randomized controlled trial to determine the effects of HBV genotype and precore/core promoter mutations on IFN-Α response in patients with HBeAg-positive chronic hepatitis. Clinical data and stored sera from 109 (95%) patients in the original trial were analyzed. Seventy-three patients received IFN-Α and 34 received no treatment (controls). Almost all patients had HBV genotypes B (38%) and C (60%). Antiviral response was achieved in 39% and 17% of IFN-Α—treated patients ( P = 0.03) and in 10% and 8% of untreated controls ( P = 0.88) with HBV genotype B and C, respectively. Multivariate analysis identified HBV genotype B, elevated pretreatment alanine aminotransferase (ALT) levels, and low pretreatment HBV-DNA levels but not IFN-Α treatment as independent factors associated with antiviral response. Among the 66 patients with elevated pretreatment ALT level, antiviral response was achieved in 57% and 21% of IFN-Α—treated patients ( P = 0.019), and in 25% and 8% of untreated controls ( P = 0.45) with HBV genotype B and C, respectively. Multivariate analysis showed that genotype B and low pretreatment HBV-DNA levels were independent predictors of antiviral response. In conclusion, our data showed that HBV genotype B was associated with a higher rate of IFN-induced HBeAg clearance compared with genotype C. Stratification for HBV genotypes should be considered in future clinical trials of antiviral therapy of chronic hepatitis B. (H EPATOLOGY 2002;36:1425–1430). | en_US |
dc.format.extent | 594672 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | W.B. Saunders | en_US |
dc.publisher | Wiley Periodiocals, Inc. | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Hepatology | en_US |
dc.title | HBV genotype B is associated with better response to interferon therapy in HBeAg( + ) chronic hepatitis than genotype C | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan, Ann Arbor, MI. | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan, Ann Arbor, MI. | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan, Ann Arbor, MI. | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan, Ann Arbor, MI. ; Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, Michigan 48109–0362. fax: 734–936–7392 | en_US |
dc.identifier.pmid | 12447868 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/38415/1/1840360619_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1053/jhep.2002.37139 | en_US |
dc.identifier.source | Hepatology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.